Pages

Tuesday, June 12, 2012

2011 Pharmacy Market Share for Specialty Drugs

As part of my ongoing efforts to illuminate the drug channel, here’s a look at the 2011 specialty pharmacy market.

According to Pembroke Consulting's research, the specialty market boomed last year. In 2011:

$46.9 billion of specialty drugs were dispensed by retail, mail, and specialty pharmacies.

Specialty drugs represented about 17% of the pharmacy industry’s total revenues.

Pharmacy revenues from specialty drugs grew by $7.7 billion (+19.7%).

Three companies—Express Scripts, CVS Caremark, and Walgreens—generate about two-thirds of revenues from pharmacy-dispensed specialty drugs. The next two largest players had a combined share of less than 4%.

Read on for market share estimates for the top 7 (now top 5) players, along with observations on the market's evolution and implications for manufacturers.A DIVERSE MARKET

Although a majority of specialty drugs dispensed by a pharmacy to a patient are sold via a specialty pharmacy, any licensed pharmacy can dispense a specialty drug as long as the product can be purchased from a manufacturer or via an authorized wholesale distribution channel.

As a result, numerous pharmacies with specialty drug capabilities compete vigorously to dispense these expensive therapies. Pharmacies dispensing specialty drugs are operated by such organizations as health plans, pharmaceutical wholesalers, retail pharmacy chains, physician practices, and PBMs. There are also many independent specialty pharmacies.

Here’s a brief summary illustrating specialty pharmacies' diverse ownership, along with some examples. (Please don't take it personally if your company wasn't included!)

Despite this diversity, market share remains highly concentrated. If we account for the 2012 combinations (Express Scripts/Medco and Walgreens/Bioscrip), then the top three companies accounted for about two-thirds of 2011's specialty drug revenues via pharmacies.

Observations:

Pharmacy Benefit Managers (PBMs) remain the largest participants in the specialty pharmacy market. In 2011, the combined market share of Express Scripts and Medco Health Solutions was 30.5%, slightly down from 2010’s combined share. This figure will decline further in 2013 due to Medco’s contract losses, especially the OptumRx business now migrating in-house to UnitedHealth.

Omnicare's Advanced Care Scripts pharmacy appears on the list for the first time. However, I wonder about Omincare's strategy given yesterday's executive departure. On Monday, CEO John Figueroa unexpectedly "resigned."

Pharmacy revenues from specialty drugs exclude specialty pharmaceuticals utilized at non-retail outlets such as clinics and hospital pharmacies. Specialty distributors typically handle office-administered agents (infused or healthcare-practitioner-administered medications) covered by a patient’s medical benefit vs. the self-administered agents dispensed by specialty pharmacies. These channels are starting to compete more directly, as I discuss in New Data on Specialty Pharmacy’s Challenge to Buy-and-Bill.

Given the diverse ownership illustrated in the above table, manufacturers will need cross-organization coordination as specialty customers, service providers, and channels consolidate. For instance, manufacturer can limit undue influence from organized customers by maintaining internal firewalls and separate account responsibility based on functional roles within the specialty channel system.

Specialty drugs are fast becoming the pharmaceutical industry's future, so stay tuned to Drug Channels for further updates.

DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc. or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc. does not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc. or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Pembroke Consulting or the author. Neither Pembroke Consulting nor the author endorse or approve of their content. Pembroke Consulting and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., or any of its employees.